Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

Mayo Clinic, Rochester, MN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Rochester, MN
Treatments:Biologic therapyHospital:Mayo Clinic
Drugs:Journal:Link
Date:Aug 2005

Description:

Patients: This Phase II trial involved 65 patients with newly diagnosed glioblastoma multiforme (GBM). There were 38 men and 27 women, and the median age was 54 years. Prior to the start of this trial, thirty patients also received anticonvulsants and twenty-nine had been on chemotherapy.

Treatment: The treatment consisted of onebiological agent: temsirolimus.

Toxicity: Two deaths "possibly related to treatment" were observed (pneumonia and pneumonitis). Grade 3 hematologic toxicities included thrombocytopenia. Grade 3 or higher nonhematologic toxicities included hypercholesterolemia, hypertriglyceridemia, hyperglycemia, rash, and fatigue.

Results: The median overall survival was 4.4 months.

Support: One author owns stock with and is employed by Wyeth. Wyeth develops and manufactures temsirolimus.

Correspondence: Evanthia Galanis, MD, DSc.





Back